WHO: Excipients GMP Guideline published for Comments

Recommendation
8-10 April 2025
Vienna, Austria
Contents of the regulatory information in the ASMF and CEP
In March 2023, the WHO published the first draft of the guideline "WHO good manufacturing practices for excipients used in pharmaceutical products" on its website for comments. The public comment period ends on 26 May 2023, so that notes and comments can still be submitted until then. The proposals will then be reviewed and the resulting draft is expected to be discussed by a consultation group in July 2023.
The current draft is based on "The WHO guideline Good Manufacturing Practices: supplementary guidelines for the manufacture of pharmaceutical excipients", which was published in 1999 as Annex 5 in the WHO Technical Report Series No 885. This annex was the starting point for the guideline which can now be commented on.
The current proposal of the new guideline is divided into 18 chapters, partly with subchapters. The individual chapters are listed below:
1. Introduction and scope
2. Glossary
3. Quality management
- Quality Risk Management
- Management review
4. Complaints
5. Recalls
6. Returns
7. Self-inspection, quality audits and supplier's audits and approvals
8. Personnel
9. Sanitation and hygiene
10. Documentation
- Standard operating procedures and records
- Specifications
- Batch documentation
- Labels
11. Premises
12. Equipment and utilities
13. Materials
14. Production
- Rework
- Reprocessing
15. Qualification and validation
16. Quality control
17. Product life cycle and continuous improvement
18. Storage and distribution
- Storage
- Distribution
You can view and comment on the draft guideline "WHO good manufacturing practices for excipients used in pharmaceutical products" on the WHO website.
Related GMP News
31.03.2025WHO: Update of Guideline of Reference Standards
26.03.2025EMA: Update of "PLM Portal eAF - Release Notes"
26.03.2025PFAS Restriction in the EU: Pharma Deutschland and VDDI request Comprehensive Exemptions
26.03.2025CMDh/EMA: Appendix 1 for Nitrosamines Revised
20.03.2025PFAS in the Healthcare Sector: Innovations for a Sustainable Future in Europe
05.03.2025FDA Warning Letter caused by insufficient Documentation Practices